CAPRICOR THERAPEUTICS, INC. Earnings Per Share Diluted

• CAPRICOR THERAPEUTICS, INC. showed a decrease of -96.5% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from CAPRICOR THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
• XBRL data for this metric is available from 2016 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2020: $0.23 (loss) per share | Q3 2020: $0.23 (loss) per share | Q1 2021: $0.23 (loss) per share | Q2 2021: $0.21 (loss) per share | Q3 2021: $0.17 (loss) per share | Q1 2022: $0.32 (loss) per share | Q2 2022: $0.29 (loss) per share | Q3 2022: $0.26 (loss) per share | Q1 2023: $0.31 (loss) per share | Q2 2023: $0.29 (loss) per share | Q3 2023: $0.25 (loss) per share | Q1 2024: $0.31 (loss) per share | Q2 2024: $0.35 (loss) per share | Q3 2024: $0.38 (loss) per share | Q1 2025: $0.53 (loss) per share | Q2 2025: $0.57 (loss) per share | Q3 2025: $0.54 (loss) per share.
• Over the full 9 years of available data (2016 to 2025), CAPRICOR THERAPEUTICS, INC.'s Earnings Per Share Diluted has declined by 123.8%.
• Historical annual values: Fiscal year 2025: $2.26 (loss) per share | Fiscal year 2024: $1.15 (loss) per share | Fiscal year 2023: $0.83 (loss) per share | Fiscal year 2022: $1.18 (loss) per share | Fiscal year 2021: $0.87 (loss) per share | Fiscal year 2020: $0.88 (loss) per share | Fiscal year 2018: $0.52 (loss) per share | Fiscal year 2017: $0.09 per share | Fiscal year 2016: $1.01 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026